UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------------------------------------------------------------
FORM 10-K/A
Amendment No. 2
(Mark One)
|X| ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended December 25, 2004
|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
-------------------- --------------------
Commission file number: 1-11064
------------------------------------------------------------------------------
BRITESMILE, INC.
(Exact name of registrant as specified in its charter)
Utah 87-0410364
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
460 North Wiget Lane, Walnut Creek, California, 94598
(Address of principal executive offices, Zip Code)
(925) 941-6260
(Registrant's telephone number, including area code)
------------------------------------------------------------------------------
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, Par Value $0.001 Per Share
------------------------------------------------------------------------------
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes |X| No |_|
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. |_|
Indicate by check mark whether the registrant is an accelerated filer
(as defined in Rule 12b-2 of the Act). Yes |_| No |X|
The aggregate market value of common stock held by non-affiliates of
the registrant as of June 26, 2004 was approximately $23,409,614.
The number of shares outstanding of the registrant's common stock as of
August 15, 2005 was 10,549,130.
DOCUMENTS INCORPORATED BY REFERENCE: None.
================================================================================
================================================================================
Explanatory Note to Form 10-K/A Amendment No. 2
This Amendment No. 2 to the Annual Report on Form 10-K, as amended by Amendment
No. 1 thereto (the "Annual Report"), of BriteSmile, Inc. (the "Company") is
being filed in response to comments received from the Securities and Exchange
Commission to the Company's Preliminary Proxy Statement for its 2005 Annual
Meeting of Stockholders, including to correctly refer to Accounting Principles
Board Opinion No. 14, which was erroneously referred to as Statement of
Financial Accounting Standards No. 14, in footnote 7 to the Company's
consolidated financial statements included in Item 8 of the Annual Report. There
have been no changes to the financial data.
This Amendment No. 2 speaks as of the date it is filed and reflects only the
changes to Items 8 and 9A of Part II, Items 10, 11 and 13 of Part III and Item
15 of Part IV set forth below. No other information in the Annual Report,
including the other information set forth in our financial statements and the
footnotes thereto, has been modified or updated in any way.
PART II.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The Company's consolidated financial statements and associated notes are
amended only to delete footnote 7 to the Company's consolidated financial
statements and replace it with the following to correctly refer to Accounting
Principles Board Opinion No. 14, which was erroneously referred to as Statement
of Financial Accounting Standards No. 14 under the caption "Convertible Debt"
therein.
7. Financing Arrangements
Following is a summary of the Company's outstanding debt financing
arrangements (in thousands):
December 25, December 27,
2004 2003
------------- -------------
Bridge loan payable to LCO $ -- $ 2,000
Preferred Stock - BDI 1,000 1,000
Note payable - Intellectual property -- 800
Note Payable to LCO, (net of discount of $1,299 and $1,560
respectively) 701 440
Note Payable to EVL -- 1,083
CAP America Trust Center Loan 1,551 1,551
EVL variable rent (See note 5) 2,546 329
Convertible debt, net of discount of $6,875 5,125 --
Financial instrument related to convertible debt - warrants 1,201 --
Financial instrument related to convertible debt - AIR 432 --
Financial instrument related to convertible debt - conversion
option 3,401 --
------------- -------------
Total outstanding debt 15,957 7,203
Less current portion (532) (3,039)
------------- -------------
Long-term debt $ 15,425 $ 4,164
------------- -------------
The following table presents the approximate annual maturities of debt (in
thousands):
2005 $ 100
2006 3,833
2007 5,946
2
2008 6,500
2009 1,718
Thereafter 1,000
----------
Total $ 19,097
Less future amortization of discounts and mark-to-market of Financial instruments related
to convertible debt (3,140)
----------
Total debt, net of discounts $ 15,957
----------
Bridge loan Payable to LCO
In November 2003, the Company borrowed $2.0 million from LCO Investments
Limited ("LCO"), a related party as described in Note 10, for general working
capital purposes. This note was repaid in January 2004, including interest at
LIBOR plus 250 basis points, 4.0% at December 27, 2003.
Preferred Stock - BDI
In August 2003, BDI issued $1.0 million of preferred stock to LCO.
Dividends are computed at the 1-year LIBOR rate plus 2% and adjust annually on
the anniversary date. The dividend rate was reset in August 2004 from 3.39% to
4.24%. Dividends are payable annually. The preferred stock is not convertible
and is redeemable in the event of certain circumstances. The Company has
recorded this preferred stock as a long-term liability.
Note payable - Intellectual property
As described in Note 2, in July 2003 BDI acquired intellectual property
from a related party for a purchase price of $6.4 million of which $800,000 was
payable in quarterly installments over one year. This note was non-interest
bearing, and was paid in full in 2004.
Note Payable to LCO
During 2003 the Company borrowed a total of $2 million from LCO. Interest
on these loans is accrued monthly at a rate of 1-year LIBOR plus 200 basis
points. The rate is reset every thirty days. The notes included detachable
warrants to purchase 333,335 shares of common stock at $6.00 per share. The fair
value of these warrants, $1.7 million, is recorded as debt discount and being
amortized to interest expense, using the effective interest method. The carrying
value at December 25, 2004 was $701,000 net of $1,299,000 unamortized discount.
This note is due in two payments of $1 million each on May 9, 2008 and July 23,
2008.
Note Payable to EVL
In March 2001, the Company borrowed $2.5 million from EVL for general
working capital. The loan had a maturity date of May 10, 2006. Payments under
the loan consist of "fixed payments" of interest, "variable payments" of
principal and interest and a "final payment" of principal. Fixed monthly
payments of $12,500 are due during the loan period. Variable payments are $25
for each LATW procedure performed at the Company's Centers. For 2004, 2003 and
2002 variable payments totaled $568,000, $718,000 and $717,000, respectively, of
which $68,000, $218,000 and $217,000, respectively was allocated to interest.
This note was repaid in August 2004.
CAP America Trust Center Loan
In May, 2003 the Company and CAP America Trust, a related party, entered
into a Loan Agreement for $2.5 million to be used for capital expenditures and
other specific revenue generating initiatives to be agreed and defined by
BriteSmile and CAP America Trust. The Company may borrow until May 10, 2006. Up
to $1.7 million of loan proceeds may be used for the specific revenue generating
initiatives, and up to $800,000 for general working capital. The Company has
drawn down $1.6 million under this loan as of December 25, 2004 at 6%, and had
3
$900,000 available for working capital needs and revenue generating initiatives.
Payments under the loan consist of "fixed payments" of interest, "variable
payments" of principal and interest and a "final payment" of principal. Variable
payments are $25 for each LATW procedure performed at the Company's Centers,
with the first $500,000 applied to principal and the remaining payments applied
to interest during each calendar year. Variable payments begin on May 11, 2006.
Convertible Debt
In December 2004, BriteSmile sold to six investors in a private placement
$12 million of convertible debt (the "Convertible Debt") that is to be repaid
over 36 months beginning in June 2006 in cash or registered stock. The
Convertible Debt is convertible into common shares of the Company at a
conversion price of $7.61 per share, which is 115% of the volume-weighted
average price of the common stock during the 10-day period prior to the
transaction date. In addition, the investors were issued five-year warrants to
purchase 544,253 shares of common stock at an exercise price of $7.61 per share
(the "Financial Instruments Related to Convertible Debt - Warrants"). The
investors also have an additional investment right that gives the investors the
option within 180 trading days to loan the Company up to an additional $4
million under the same terms (the "Financial Instruments Related to Convertible
Debt - AIR"). The Financial Instruments Related to Convertible Debt - Warrants
and the Financial Instruments - AIR together are the "Financial Instruments
Related to Convertible Debt". In connection with the December 2004 financing,
the Company filed a registration statement with the SEC in January 2005 to cover
the underlying shares for the transaction. The SEC declared the registration
statement effective in February 2005.
The Company allocated the net proceeds from the sale of the Convertible
Debt between the Convertible Debt, the Financial Instruments Related to
Convertible Debt - Warrants, and the Financial Instruments Related to
Convertible Debt - AIR based on their relative fair values. The Company employed
the Black-Scholes model to value the embedded conversion option of the
Convertible Debt. The relative fair values of the Financial Instruments Related
to Convertible Debt - Warrants and the Financial Instruments Related to
Convertible Debt - AIR, and the fair value of the embedded conversion option
resulted in the recording of a discount on the Convertible Debt. The table below
details the accounting treatment of the Convertible Debt in thousands.
Proceeds of the convertible debt $ 12,000
Issuance costs incurred 836
--------------------
Net proceeds of the convertible debt $ 11,164
====================
Allocation of convertible debt proceeds:
Allocated relative fair value of financial instrument related to convertible debt - warrants $ 1,429
Allocated relative fair value of financial instrument related to convertible debt - AIRs 654
Fair value of financial instrument related to convertible debt - conversion option 4,011
Fair value of convertible debt, net of discount 5,070
--------------------
Total net proceeds of the convertible debt $ 11,164
====================
Balance sheet presentation of convertible debt at December 25, 2004:
Net carrying value of convertible debt prior to amortization and mark-to-market adjustment $ 11,164
Less: mark-to-market adjustment (1,060)
Amortization of discount 55
--------------------
Net carrying value of convertible debt at December 25, 2004 $ 10,159
====================
Net carrying value of convertible debt at December 25, 2004 - current $ 432
====================
Net carrying value of convertible debt at December 25, 2004 - non current $ 9,727
====================
4
In accordance with APB No. 14, the Company has accounted for the Financial
Instruments Related to Convertible Debt - Warrants separately as freestanding
instruments. The value of the Financial Instruments Related to Convertible Debt
- Warrants was determined utilizing the Black-Scholes option pricing model,
which is consistent with the Company's historical valuation methods. The
following assumptions and estimates were used in the Black-Scholes model:
volatility of 0.600; an average risk-free interest rate of 3.50%; dividend yield
of 0%; and an expected life of 4.42 years. The value of the Financial
Instruments Related to Convertible Debt - Warrants has been recorded as a
long-term liability and was marked to market on December 25, 2004. The value of
the Financial Instruments Related to Convertible Debt - Warrants on the
effective date of the transaction was $1.4 million. Utilizing the Black-Scholes
option pricing model, the mark to market adjustment for the re-measurement
period ended December 25, 2004 was a $228,000 reduction in fair value.
In accordance with APB No. 14, the Company has accounted for the Financial
Instruments Related to Convertible Debt - Additional Investment Rights
separately as freestanding instruments. The value of the Financial Instruments
Related to Convertible Debt - Additional Investment Rights was determined
utilizing the Black-Scholes option pricing model, which is consistent with the
Company's historical valuation methods. The following assumptions and estimates
were used in the Black-Scholes model: volatility of 0.600; an average risk-free
interest rate of 3.50%; dividend yield of 0%; and an expected life of 0.75
years. The value of the Financial Instruments Related to Convertible Debt -
Additional Investment Rights has been recorded as a current liability and was
marked to market on December 25, 2004. The value of the Financial Instruments
Related to Convertible Debt - Additional Investment Rights on the effective date
of the transaction was $654,000. Utilizing the Black-Scholes option pricing
model, the mark to market adjustment for the re-measurement period ended
December 25, 2004 was a $222,000 reduction in fair value.
In accordance with SFAS No. 133, the Company has accounted for the
Financial Instruments Related to Convertible Debt - Conversion Option as a
freestanding instrument. The value of the Financial Instruments Related to
Convertible Debt - Conversion Option was determined utilizing the Black-Scholes
option pricing model, which is consistent with the Company's historical
valuation methods. The following assumptions and estimates were used in the
Black-Scholes model: volatility of 0.600; an average risk-free interest rate of
3.50%; dividend yield of 0%; and an average expected life of 2.88 years. The
value of the Financial Instruments Related to Convertible Debt - Conversion
Option has been recorded as a current liability and was marked to market on
December 25, 2004. The value of the Financial Instruments Related to Convertible
Debt - Conversion Option on the effective date of the transaction was $4.0
million. Utilizing the Black-Scholes option pricing model, the mark to market
adjustment for the re-measurement period ended December 25, 2004 was a $611,000
reduction in fair value.
The total mark to market adjustments resulted in a gain of $1.1 million for
the re-measurement period ended December 25, 2004.
The discount on the Convertible Debt will be amortized to interest expense
over the 53-month period to the maturity of the Convertible Debt using the
effective yield method. The Convertible Debt accrues interest at the greater of
5% or 6-month LIBOR plus 300 basis points (capped at 8%) payable in cash or
registered stock. Interest is payable quarterly in arrears. The first interest
payment date was March 31, 2005.
CAP Advisers Line of Credit
In December 2001, BriteSmile International, a subsidiary of the Company,
entered into Credit and Security Agreements (the "Credit Agreements") with CAP
Advisers Limited ("CAP Advisers"), a related party as described Note 10, which
provided for a $6.5 million line of credit. During 2003, CAP Advisers assigned
their interest in the outstanding balance to LCO. In November 2003, LCO agreed
to accept 511,813 shares of restricted Common stock of the Company in full
satisfaction of the outstanding loan balance of $6.5 million. The conversion
price for the shares was $12.70 per share.
2% Convertible Promissory Note
In November 2002, the Company sold to two investors in a private placement
2% convertible notes, which were due and payable on November 20, 2005 (the
"November 2002 Notes"). The November 2002 Notes were convertible into shares of
5
common stock of the Company at a conversion rate of $2.40 per share. The two
investors, who purchased the November 2002 Notes, both affiliates of the
Company, are: LCO ($2.5 million) and Bradford G. Peters ($1.0 million). The CEO
of the Company funded an additional $500,000 in 2003 under the same terms,
pursuant to a subscription agreement.
During 2003 the entire $4 million was converted into 1,250,000 shares of
common stock, per the terms of the agreement.
5% Subordinated Convertible Notes
During 2003, $800,000 of the remaining 5% convertible notes was converted
into 335,333 shares of common stock at $2.40 per share. These notes were
originally issued by the Company in August 2000 with detachable warrants with an
exercise price that adjusts based on subsequent issuances. During 2002, the
Company recorded a deemed dividend of $307,000 representing the change in the
value of warrants due to the change of the exercise price of the warrants. Of
the original warrants issued with the August 2000 Note Offering, 251,053
warrants remain outstanding.
ITEM 9A. CONTROLS AND PROCEDURES
Company management is aware of certain deficiencies in the design or
operation of the Company's disclosure controls and internal accounting controls.
In connection with its audit of the Company's 2004 financial statements,
Deloitte & Touche LLP, the Company's former independent registered public
accounting firm reported that (1) inadequacies in the design and execution of
the Company's internal control structure, and (2) improper application of
accounting principles in accordance with GAAP, constitute material weaknesses in
the Company's internal control structure for the year ended December 25, 2004.
The inadequacies in the Company's control structure included deficiencies or
inadequacies in the following specific areas: payments made to vendors without
adequate supporting documents, communication of all transactions to the
financial department, segregation of duties among finance department employees,
recording of inventory and physical inventory counts, tracking of fixed assets,
and timely completion of account reconciliations. Although any one of the
foregoing categories may not relate to material dollar amounts, in the aggregate
they represent a material weakness in the Company's internal control structure.
With respect to any specific adjustments identified in the audit process related
to improper application of accounting principles or inadequacy of internal
controls, the Company believes that all such adjustments have been made.
The Company's management, with the participation of its Principal Executive
Officer and Chief Financial Officer, have evaluated the effectiveness of the
Company's "disclosure controls and procedures" (as defined in Exchange Act Rule
13a-15(e)) as of the end of the period covered by this report. During the course
of the evaluation, the additional procedures performed and controls instituted
by the Company to enhance its internal controls and mitigate the effect of
deficiencies and to prevent misstatements or omissions in its consolidated
financial statements were considered. Based on this evaluation, the Company's
Principal Executive Officer and Chief Financial Officer concluded that as a
result of the material weaknesses referred to above, the Company's disclosure
controls and procedures are not effective as of the end of the period covered
by this report.
The Company has made, and will continue to make, improvements to its
policies, procedures, systems and staff who have significant roles in disclosure
controls and in internal controls over financial reporting, to address the
identified deficiencies. In addition, management has begun its project to comply
with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002.
Management anticipates that this effort will also help to more formally
document, communicate, and comply with the Company's accounting policies and
procedures, as well as to identify and rectify any residual disclosure or
reporting process control issues that may exist but, at this time, are unknown
to management.
6
PART III.
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The following sets forth the name, age and position of each director and
executive officer of the Company as of the date of this Report:
Name Age Position with the Company
---- --- -------------------------
Anthony M. Pilaro................ 69 Chairman of the Board of Directors
Gregg Coccari.................... 52 Director
R. Eric Montgomery............... 50 Director
Bradford Peters.................. 37 Director
Harry Thompson................... 75 Director
Peter Schechter.................. 46 Director
L. Tim Pierce.................... 53 Director
Dr. Julian Feneley............... 41 President and Director
Ken Czaja........................ 56 Executive Vice President, Chief Financial Officer and Secretary
Robert Sieban.................... 36 Executive Vice-President, BriteSmile Whitening Centers
Nhat Ngo......................... 32 Executive Vice President, Business Development and General Counsel
Anthony M. Pilaro
Mr. Pilaro has served as a director and Chairman of the Board of the
Company since August 1997. Presently, he serves as Chairman of CAP Advisers
Limited, with offices in Dublin, Ireland, and which serves as a family office
for the business affairs of the Pilaro family. He is also founder and Chairman
of Excimer Vision Leasing L.P., a partnership primarily engaged in the business
of leasing Excimer laser systems. Mr. Pilaro was Chairman of both CAP and
Excimer Vision Leasing for the last 5 years except for the period from August
2004 to February 2005. Mr. Pilaro has been involved in private international
investment banking. He was a Founding Director and former Chief Executive
Officer of Duty Free Shoppers Group Limited, the world's leading specialty
retailer catering to international travelers, and a founder of the predecessor
of VISX, Inc. A graduate of the University of Virginia and the University of
Virginia Law School, Mr. Pilaro practiced law in New York City through 1964.
Gregg Coccari
Mr. Coccari served as Chief Executive Officer of the Company between
January and June 2005 and has served as a director of the Company since January
2005. Previously, from 1992 to 2004, Mr. Coccari was President and CEO of
Teleflora, one of the world's largest floral wire services with operations
throughout North America. Prior to Teleflora, from 1988 to 1992, Mr. Coccari was
a Senior Managing Director at Franklin Mint, a seller of collectibles. Prior to
Franklin Mint, Mr. Coccari held various management positions at Eagle's Eye, a
wholesaler of clothing, and Johnson & Johnson. Mr. Coccari received a B.S. from
Colgate University and an M.B.A. from Wharton School of the University of
Pennsylvania.
R. Eric Montgomery
Mr. Montgomery has served as a director of the Company since May 1998. He
is a consultant, researcher, and entrepreneur in the oral care and cosmetic
products industries, and has been granted over 65 US and foreign patents since
1981. Prior to his appointment to the Company's Board of Directors, from
November 1997 until May 1998, Mr. Montgomery served as an independent consultant
to the Company through Applied Dental Sciences, Inc. Mr. Montgomery is also the
7
Founding Manager and President of Oraceutical LLC, an organization that develops
products and technologies for dentistry and consumer oral care. Oraceutical is
currently engaged by the Company as an independent contractor to provide
technology development services. Mr. Montgomery's companies have provided
consulting services to and developed products for oral care and pharmaceutical
companies, and now also provide order fulfillment outsourcing services for
BriteSmile.
Bradford Peters
Mr. Peters has served as a director of the Company since December 1999. He
is the President of Blackfin Capital, a privately held investment company based
in New York. Prior to founding Blackfin Capital, from July 1993 to June 1998,
Mr. Peters was with Morgan Stanley Private Wealth Management Group. Mr. Peters
received an M.B.A. from Duke University.
Harry Thompson
Mr. Thompson has served as a director of the Company since December 1999.
He has also been President of The Strategy Group, a management consulting firm,
for the last 15 years, and was Managing Director of Swiss Army Brands, Inc., a
consumer products company, from 1988 to 2003. Prior to founding The Strategy
Group, Mr. Thompson served in senior management of several core units of the
Interpublic Group of Companies, one of the world's leading advertising groups.
Mr. Thompson also has served as either manager or chairman of several
telecommunication companies of The Galesi Group. Mr. Thompson received an M.B.A.
from Harvard Business School.
Peter Schechter
Mr. Schechter has served as a director of the Company since July 1999. Mr.
Schechter is a founding partner of Chlopak, Leonard, Schechter and Associates
since 1993, an international communications consulting firm specializing in the
management of crisis communications, corporate reputation programs, political
campaigns and country image initiatives. Mr. Schechter has extensive experience
in public policy management. A graduate of the School of Advanced International
Studies at Johns Hopkins University, Mr. Schechter has lived in Europe and Latin
America. He is fluent in six languages.
L. Tim Pierce
Mr. Pierce, a certified public accountant, has served as a director of the
Company since February 2003. Mr. Pierce is currently serving as a Director,
Executive Vice President and the Chief Financial Officer and Corporate Secretary
of E&O Holdings, Inc., and its wholly owned subsidiaries: SBI Services, Inc., a
provider of administrative support services, and SBI Enteris Inc., a technology
consulting services organization. He joined SBI and Company (the former parent
of SBI Services, Inc.) in April 1998. SBI and Company was sold in July 2004. Mr.
Pierce worked for Mrs. Fields' Original Cookies, Inc. from 1988 through 1998,
where he served most recently as Mrs. Fields' Senior Vice President, Chief
Financial Officer, and Corporate Secretary. For twelve years from 1976 to 1988,
Mr. Pierce served as an auditor with Price Waterhouse and Deloitte & Touche. Mr.
Pierce is currently a director of E&O Holdings, Inc. Mr. Pierce is a member of
the American Institute of Certified Public Accountants, and the Utah Association
of Certified Public Accountants. Mr. Pierce is considered by the Company to be
an audit committee financial expert. Mr. Pierce received his B.S. from Brigham
Young University.
Dr. Julian Feneley
Dr. Feneley has served as a director of the Company since December 2003.
Dr. Feneley began working on BriteSmile matters in January 2002 as a consultant
to an affiliate of the Company, focusing on strategic and development
initiatives. He was appointed Chairman of BriteSmile Development, Inc. in May
2003, and President of BriteSmile, Inc. in February 2004. In June 2005, Dr.
Feneley also assumed the duties of Chief Executive Officer formerly carried out
by Gregg Coccari. Previously, Dr Feneley co-founded narrowbridge, an e-customer
acquisition technology company, where he served as CEO from 2000 to 2001, and
Bioscience Managers, a biotechnology venture capital and corporate finance
boutique, where he served as Head of Corporate Finance from 2001 to 2003. Prior
to 2000, Dr. Feneley headed the European healthcare investment banking franchise
of J P Morgan during its period as the globally ranked #1 investment bank in
this industry sector. Dr. Feneley originated and executed transactions with an
aggregate volume in excess of $200 billion, including the then largest merger in
corporate history. Prior to joining J P Morgan in 1990, Dr. Feneley qualified
and worked as a medical doctor at the renowned Guy's Hospital in London,
England.
8
Ken Czaja
Mr. Czaja was appointed Chief Financial Officer and Secretary of BriteSmile
in May 2004. He brings to the Company a wealth of finance management experience
spanning small and large public global technology companies. Prior to joining
the Company, from October 2002 to January 2004, Mr. Czaja was CFO of
PerkinElmer's OptoElectronics Group (a developer and manufacturer of specialty
lighting and sensor products). Before PerkinElmer, from May 2001 to October
2002, he was CFO of BrightStar, a small publicly traded services firm
specializing in Information Technology solutions. Prior to BrightStar, from 1996
to June 2000, Mr. Czaja was CFO of IntelliCorp, a publicly traded software firm,
and before that, Vice President of Finance for Wyse Technology, a mid-size
computer terminal and monitor company. He began his career progressing through
numerous financial management positions at Xerox Corporation. Mr. Czaja received
a B.S. degree in physics from Columbia University and a Masters degree in
industrial management from Georgia Institute of Technology.
Robert Sieban
Effective June 1, 2003, Robert Sieban joined BriteSmile as Executive Vice
President, BriteSmile Whitening Centers. A veteran of the retail industry, Mr.
Sieban is responsible for BriteSmile's Center Division. Mr. Sieban is also
responsible for retail sales of BriteSmile's expanding proprietary oral care
products. Mr. Sieban comes to BriteSmile with over 10 years retail experience
including his most recent position as Senior Vice President of Retail Stores for
Illuminations from September 2001 to May 2003. Illuminations is a natioinwide
home furnishings retail organization. Prior to Illuminations, Mr. Sieban was
also Senior Vice President of Stores for Lids Corporation, a retailer
specializing in headwear, from June 1998 to June 2001.
Nhat H. Ngo
In November 2004, Nhat Ngo was appointed Executive Vice President, Business
Development & Planning and General Counsel. Mr. Ngo was named the Chief
Operating Officer of BriteSmile Development, Inc., the Company's subsidiary, in
April 2003 to oversee BriteSmile Development's research and development efforts
and to manage its intellectual property portfolio. Prior to joining the Company
in June 1999 as Director of Sales, Mr. Ngo practiced law at Shaw Pittman in
Washington D.C. Mr. Ngo served as Vice President, National Sales Director for
the Company from 2000 to 2003, having executed an aggressive sales campaign to
expand the dental distribution channel, and was promoted to Vice President of
Business Development & Planning in March 2003. He graduated with a B.S. degree
in business from the University of Virginia McIntire School of Commerce and J.D.
degree from the University of Virginia School of Law.
There is no family relationship between any executive officer or director
of the Company and any other executive officer or director.
Audit Committee; Audit Committee Financial Expert
The Company has a separately-designated standing audit committee
established in accordance with Section 3(a)(58)(A) of the Securities Exchange
Act of 1934, as amended, that acts pursuant to a written charter adopted by the
Board of Directors. The Company's Board of Directors has determined that Tim
Pierce is an audit committee financial expert in accordance with Section 10A of
the Exchange Act of 1934, as amended.
Compliance with Section 16(A) of the Exchange Act
Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
officers, directors and persons who beneficially own more than 10 percent of a
registered class of the Company's equity securities to file reports of ownership
and changes in ownership with the Securities and Exchange Commission. Officers,
directors and greater than 10 percent shareholders are required by regulation of
the Securities and Exchange Commission to furnish the Company with copies of all
Section 16(a) forms they file.
Based solely upon the Company's review of the copies of such forms
furnished to it during the year ended December 25, 2004, and representations
made by certain persons subject to this obligation that such filings were not
9
required to be made, the Company believes that all reports required to be filed
by these individuals and persons under Section 16(a) were filed in a timely
manner, except as follows:
1. Form 4 report of Eric Montgomery filed January 20, 2004 to report a
transaction dated December 29, 2003.
2. Form 3 report of Julian Feneley filed March 16, 2004 to report Dr.
Feneley's becoming a reporting person on December 17, 2003.
3. Form 4 report of Julian Feneley filed March 17, 2004 to report a
transaction dated April 20, 2003.
4. Form 4 report of Eric Montgomery filed September 13, 2004 to report a
transaction dated September 9, 2003.
5. Form 3 report of Robert Sieban filed October 5, 2004 to report Mr. Sieban's
becoming a reporting person on June 3, 2003.
6. Form 4 report of Robert Sieban filed October 5, 2004 to report a
transaction dated September 2, 2003.
7. Form 4 report of Paul Dawson, former CEO of BriteSmile International, Inc.
filed February 7, 2005 to report a transaction dated December 14, 2004.
8. Form 4 report of Julian Feneley filed February 8, 2005 to report a
transaction dated December 14, 2004.
9. Form 4 reports of Ian Ellis filed June 14, 2004, July 23, 2004, December
22, 2004 and December 28, 2004 to report transactions dated June 9, 2004,
July 20, 2004, December 17, 2004 and December 22, 2004, respectively.
Except as disclosed, the Company is not aware of any transactions in its
outstanding securities by or on behalf of any director, executive officer or 10
percent holder, which would require the filing of any report pursuant to Section
16(a) during the year ended December 25, 2004, that has not been filed with the
Securities and Exchange Commission.
Code of Ethics
The Company has adopted a Code of Ethics that applies to directors,
officers and employees. The full text of the Company's Code of Ethics has been
filed as Exhibit 14 to the Company's Annual Report on Form 10-K for its fiscal
year ended December 27, 2003, and is incorporated herein by reference.
10
ITEM 11. EXECUTIVE COMPENSATION
The following Summary Compensation Table shows compensation paid by the
Company for services rendered during 2002, 2003 and 2004 to each person who
served as the Company's Chief Executive Officer during 2004, and to the
Company's four most highly compensated executive officers during 2004 in
addition to the Chief Executive Officers.
Long-Term
Annual Compensation Compensation
------------------------------ ---------------
Name and Principal Position Period Salary Bonus Securities Other
Underlying
Options
---------------------------------------------------- -------------- -------------- --------------- ---------------
John L. Reed (1)....................... 2004 $ 91,887 - 35,000 -
Chief Executive Officer 2003 239,636 - 41,667 -
2002 225,000 - - -
Bruce Fleming (2)...................... 2004 $ 397,479 $75,000 - -
Chief Executive Officer 2003 350,000 233,333 166,667 -
2002 175,000 - - -
Anthony Pilaro (3)..................... 2004 - - - -
Acting Chief Executive Officer 2003 - - - -
2002 - - - -
Julian Feneley (4)..................... 2004 $ 216,923 - 18,500 $67,200 (5)
President 2003 50,000 - - -
2002 - - - -
Paul Dawson (6)........................ 2004 $265,596 $54,870 15,000 -
CEO, BriteSmile International Ltd. 2003 210,000 44,370 55,002 -
2002 191,667 - - -
Robert Sieban (7)...................... 2004 $ 207,692 $37,500 6,000 -
Executive Vice President 2003 107,692 - 31,250 -
BriteSmile Centers 2002 - - - -
Stephen Miller (8)..................... 2004 $ 174,115 - 5,000 -
Executive Vice President 2003 150,000 - 9,167 -
Development and Real Estate 2002 150,000 - - -
(1) Mr. Reed served as Chief Executive Officer of the Company from June 1999
until April 2004.
(2) Mr. Fleming served as Chief Executive Officer of the Company from April
2004 until August 2004.
(3) Mr. Pilaro served as Acting Chief Executive from August 2004 until January
2005 without compensation.
(4) Dr. Feneley began working with BriteSmile in January 2002, focusing on
strategic and development initiatives, was appointed Chairman of BriteSmile
Development, Inc. a Company affiliate, in May 2003, and President of
BriteSmile, Inc. in February 2004.
(5) Represents a housing allowance paid to Dr. Feneley by a related party.
(6) Mr. Dawson resigned as CEO of BriteSmile International, Inc. effective June
11, 2005.
(7) Mr. Sieban joined the Company in June 2003.
(8) Mr. Miller, resigned as Executive Vice President for Development and Real
Estate effective July 29, 2005.
11
OPTION/SAR GRANTS IN 2004
The following table lists individual grants of stock options made during
the Company's last completed year as compensation for services rendered as an
officer of the Company:
Individual Grants
------------------------------------------------------------
Name Number of % of Total Exercise or Expiration Potential Realizable Value at
Securities Options/SARs
Underlying Granted to Assumed Annual Rates of Stock
Options/SARs Employees in Base Price Price Appreciation for Option
Granted FY 2004 ($/Share) Date Term (5)
-------------------------- ---------------- --------------- ------------- ------------- --------------------------------
5% 10%
-------------------------- ---------------- --------------- ------------- ------------- ---------------- ---------------
John L. Reed.............. 35,000 (1) 15.7% $12.30 3/31/2007 $67,857.56 $142,495.50
Julian Feneley............ 3,500 (2) 1.6% 12.75 3/17/2014 28,064.42 71,120.76
15,000 (3) 6.7% 6.53 12/14/2014 61,600.23 156,107.07
Paul Dawson............... 15,000 (3) 6.7% 6.53 12/14/2014 61,600.23 156,107.07
Robert Sieban............. 6,000 (1) 2.7% 9.72 9/2/2014 36,677.13 92,947.06
Stephen Miller............ 5,000 (4) 2.3% 8.40 11/2/2014 26,413.57 66,937.18
(1) The option was fully exercisable on the grant date.
(2) The option became fully exercisable on September 17, 2004.
(3) The option becomes exercisable in five substantially equal annual
installments beginning on December 14, 2004.
(4) The option becomes exercisable in five substantially equal annual
installments beginning on November 2, 2004.
(5) The assigned rates of growth were selected by the SEC for illustrative
purposes only and are not intended to predict or forecast further stock
prices.
AGGREGATED OPTION EXERCISES IN LAST YEAR
AND DECEMBER 25, 2004 OPTION VALUES
Shares Number of Securities Value of Unexercised
Acquired on Value Underlying Unexercised In the Money Options at
Name Exercise (#) Realized ($)(1) Options at December 25, 2004 December 25, 2004 (2)
------------------------------ -----------------------------
Exercisable Unexercisable Exercisable Unexercisable
---------------------- ------------ --------------- -------------- --------------- ------------- --------------
John L. Reed.......... - - 193,334 - $ 63,001 -
Bruce Fleming......... - - 100,000 - - -
Anthony Pilaro........ - - - - - -
Julian Feneley........ - - 6,500 12,000 - -
Paul Dawson........... 10,000 $9,500 48,002 12,000 85,054 -
Robert Sieban......... - - 18,500 18,750 - -
Stephen Miller........ - - 41,835 4,000 17,326 -
(1) Represents the amount realized upon sale of the underlying securities minus
the exercise price.
(2) Potential unrealized value is calculated as the fair market value at
December 23, 2004 ($6.20 per share), less the option exercise price, times
the number of shares.
Director Compensation
Non-employee directors of the Company, other than Mr. Pilaro who has
declined such compensation, receive options to purchase 5,000 shares of common
stock per year for each year during which they serve as a director. Directors
who serve as chairman of a Board committee receive options to purchase an
additional 10,000 shares of common stock per year of service. The exercise price
of such options is 100% of the fair market price on the date of grant. Actual
expenses incurred by outside directors are reimbursed. In addition, the chairman
of the Audit Committee receives a retainer in the amount of $2,500 per audit
committee meeting, and Mr. Thompson received $20,800 per month for his service
on the Marketing Committee between December 2004 and March 2005.
12
Employment Contracts and Termination of Employment Arrangements
Certain of the Company's executive officers whose compensation is required
to be reported in the Summary Compensation Table are or were parties to written
employment agreements with the Company as follows:
Gregg Coccari
The Company entered into an employment agreement with Gregg Coccari on
January 9, 2005. On June 29, 2005, the Company announced that Dr. Julian Feneley
had assumed the duties of Chief Executive Officer of the Company from Mr.
Coccari and that the Board of Directors of the Company had accepted Mr.
Coccari's deemed resignation as Chief Executive Officer of the Company. Under
the terms of the employment agreement with Mr. Coccari, the Company paid Mr.
Coccari an annual base salary of $350,000, and Mr. Coccari was eligible for
incentive bonuses if certain targets were met. Mr. Coccari was also granted
240,000 shares of restricted common stock, 80,000 shares of which vested upon
grant, and 160,000 additional shares of which did not vest. In addition, Mr.
Coccari received options to purchase 600,000 shares of the Company's common
stock at an exercise price of $6.30 per share. Options to purchase 120,000
shares vested on the date of the agreement. The remaining 480,000 options were
subject to vesting over time. As disclosed in the Company's quarterly report
filed on Form 10Q on August 15, 2005, Mr. Coccari has commenced an arbitration
proceeding regarding his employment contract.
Paul Dawson
Mr. Dawson terminated his employment as CEO of BriteSmile International,
Ltd. effective June 11, 2005. BriteSmile International entered into an
employment agreement with Paul Dawson on April 19, 1999. Under the terms of the
agreement, Mr. Dawson served as Chief Executive Officer of BriteSmile
International, a wholly-owned subsidiary of the Company. The Company paid Mr.
Dawson (euro)210,000 per year for his services. Mr. Dawson was eligible for a
bonus based on the number of paid teeth whitening procedures performed in a
designated international area. The bonus was paid in cash and common stock of
the Company. In addition, Mr. Dawson received options to purchase 50,000 shares
of the Company's common stock at the closing price on the date of the agreement.
Options to purchase 16,667 shares vested on the date of the agreement. The
remaining 33,333 options vested in equal installments over five years.
Compensation Committee Interlocks and Insider Participation in Compensation
Decisions
The members of the Company's Compensation Committee during fiscal 2004 were
Bradford Peters, Peter Schechter and Harry Thompson. No member of the Company's
Compensation Committee is a current or former officer or employee of the Company
or any of its subsidiaries, and no director or executive officer is a director
or executive officer of any other corporation that has a director or executive
officer who is also a director of the Company.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Acquisition of Certain Human Oral Care Intellectual Property
In July 2003, BriteSmile Development Inc. ("BDI") entered into an Asset
Purchase Agreement (the "Purchase Agreement") with Eric Montgomery and certain
entities owned and controlled by him. Mr. Montgomery has been a member of the
Board of Directors of the Company. However, he is not standing for reelection to
the Board at the 2005 annual meeting of shareholders. He is also the founding
Manager and President of Oraceutical, LLC ("Oraceutical") and Oraceutical
Innovative Properties ("OIP"), which have provided consulting services to the
Company in the field of human oral care. Pursuant to the Purchase Agreement, as
subsequently amended in November 2003, BDI acquired intellectual property
consisting primarily of certain United States and foreign patents, patent
applications, continuations, continuations-in-part, trade secrets, technologies,
know-how, trademarks and trade names relating to human oral care for a purchase
price of $6.4 million, plus a 50% participation interest in third party
royalties and infringement recoveries relating to the intellectual property
acquired. A portion of the purchase price included an obligation of the Company
to pay $0.8 million to a third party in $0.2 million quarterly installments
13
beginning February 2004. These payments were completed and the obligation was
paid in full by December 2004.
Financing Arrangements for the Acquisition of Certain Human Oral Care
Intellectual Property
To finance a portion of the purchase price of the purchase of the human
oral care intellectual property described above, LCO Investments Limited ("LCO")
loaned $2.0 million to BDI under the terms of a promissory note due in May 2008,
and purchased $1 million of BDI preferred stock. LCO also received warrants to
purchase 333,335 shares of common stock of the Company at an exercise price of
$6.00 per share in consideration of its agreement to make the loans to BDI. In
addition, the Company guaranteed BDI's obligations under the promissory notes
issued to LCO. The shares of common stock underlying the warrants granted to LCO
are subject to certain limited "piggyback" registration rights in the event of
future registered public offerings of common stock sold by the Company. LCO is a
major shareholder of the Company. LCO is a wholly owned subsidiary of the ERSE
Trust. CAP Advisers Limited ("CAP") is a co-trustee of the ERSE Trust. Mr.
Pilaro, a director and Chairman of the Board of the Company, is Chairman of CAP.
Consulting Agreements with Oraceutical
In July 2003, BDI entered into a consulting agreement with OIP. Eric
Montgomery, a director of the Company until the 2005 annual meeting of
shareholders, is the founding Manager and President of OIP, which replaced a
consulting agreement with Oraceutical that was terminated in connection with the
acquisition of the human oral care intellectual property described above. Under
the consulting agreement, OIP agreed to consult exclusively for BDI and the
Company in the field of human oral care. OIP provides consulting services,
including research and product development services, intellectual property
support and general business support relating to human oral care. The agreement
requires OIP to devote a minimum of twenty (20) hours per week to performing
such services in return for a monthly retainer of $15,000. The agreement has an
initial term that expires on December 31, 2008 and thereafter automatically
extends for one year periods unless either party gives notice not to extend. BDI
will own all new intellectual property relating to human oral care arising from
work under the consulting agreement.
Fulfillment Services Agreement with Oraceutical
In 2004, the Company entered into an agreement with Oraceutical to provide
distribution fulfillment services for the distribution of the Company's gel and
gel kits that are used by BriteSmile's Associated Center dentists and its
Company-run Centers to perform their whitening procedures, with a plan to expand
the services to include distribution of the Company's retail products such as
toothpaste, mouthwash, and its whitening pen, BriteSmile-To-Go. Regarding the
fulfillment of gel and gel kit orders, the inventory is owned by Oraceutical
until they ship the gel or kits to BriteSmile or its customers based on orders
placed by BriteSmile to Oraceutical. The fee charged by Oraceutical for their
gel kit fulfillment services is included in the unit product cost charged by
Oraceutical to BriteSmile. The contract has an initial term of 5 years and will
automatically renew unless terminated for reason of default or convenience. If
Oraceutical wishes to terminate for convenience, they must give BriteSmile at
least 6 months notice.
Repayment of November 2003 LCO Bridge Loan
In November 2003, the Company borrowed $2.0 million from LCO for general
working capital purposes. This bridge loan was repaid in full (with accrued
interest) and terminated on January 5, 2004 using proceeds from the $8.5 million
private placement that closed in January 2004.
LCO Properties Sublease
On December 1, 1999, the Company, as sublessee, entered into an Agreement
of Sublease with LCO Properties, Inc., a Delaware corporation, as lessor. LCO
Properties, Inc. is affiliated with LCO, a major shareholder of the Company. The
Sublease covers approximately 4,821 square feet of space located in New York
City for one of the Company's teeth whitening Centers. The term of the sublease
is ten years with initial lease payments of $402,000 per year, subject to
increase in the event of increases in the rent payable under the primary lease
for the property between LCO Properties, Inc. and its lessor.
14
Harry Thompson Consulting Agreement
In August 1999, Harry Thompson, a member of the Company's Board of
Directors, agreed to provide marketing consulting services to the Company. In
consideration for Mr. Thompson's services to the Company, and pursuant to a
letter agreement dated August 17, 1999, LCO granted to Mr. Thompson the right to
purchase from LCO up to 16,668 shares of common stock of the Company at a price
of $9.00 per share. The option to purchase from LCO expired on August 31, 2004.
Public Relations Services Agreement
On April 7, 1999, the Company entered into a Letter Agreement with Chlopak,
Leonard, Schechter and Associates ("CLS"), a public relations firm in
Washington, D.C, pursuant to which CLS provided public relations advice and
served as communications counselors to the Company during 2004 for consideration
of $18,000 per month, plus expenses, from January to March and of $22,500 per
month, plus expenses, for the remainder of 2004. This relationship was
terminated as of February, 2005. Peter Schechter, a member of the Company's
Board of Directors, is one of three managing partners of CLS.
EVL Lease Agreement
The Company is party to an equipment lease in the amount of $15 million
with Excimer Vision Leasing L.P. ("EVL"), pursuant to which the Company leases
3,000 BS3000 whitening devices. Under the terms of the lease, the Company pays
(i) a fixed monthly payment of principal and interest of $75,000 and (ii)
variable rent payments equal to $25 per LATW procedure on the leased whitening
devices. Rental expense related to variable rent was $2.22 million, $2.22
million and $2.15 million for 2004, 2003 and 2002, respectively. In December
2003, the lease agreement was amended to provide that both the fixed and
variable rent portion of the monthly payment due beginning November 1, 2003
would be deferred and paid to EVL on February 15, 2005, with interest payable on
the deferred amount at a rate equal to LIBOR, plus 250 basis points. Prepayment
of these amounts in full or in part can be made without penalty. In August 2004,
the lease agreement was further amended to provide that the total rents deferred
under the November 2003 lease amendment would be deferred further and due as
follows: $1.0 million on February 15, 2005, which payment has been made; $1.0 on
February 15, 2006; and the remaining balance on February 15, 2007. In July 2005,
the lease agreement was further amended to provide that on December 31, 2005,
EVL shall sell to BriteSmile each leased device remaining under lease at a price
of $1 per device, and the term of the lease shall end as of December 31, 2005,
with no additional payments due under the lease after that date except for
variable and fixed fees unpaid as of the date of the sale and any remaining
deferred lease payments owed by BriteSmile for the August 2004 amendment to
the lease. As of December 25, 2004, the unpaid variable rent was $2.5 million.
Mr. Pilaro, the Company's Chairman, serves as Chairman of EVL, and an affiliate
of LCO owns 70% of EVL.
EVL Loan Agreement
On March 1, 2001, the Company borrowed $2.5 million from EVL for general
working capital. The loan matures on May 10, 2006 and may be prepaid at any time
without penalty. Payments under the loan consist of fixed payments of interest,
variable payments of principal and interest and a final payment of principal.
For 2004, 2003, and 2002, variable payments totaled $568,000, $718,000, and
$717,000, respectively. This loan was repaid in full in August 2004.
CAP America Trust Center Loan
In May 2003, the Company entered into a loan agreement with CAP America
Trust providing for a line of credit of up to $2.5 million, of which $0.8
million was available for working capital expenditures and $1.7 million was
available for specific revenue generating initiatives to be agreed and defined
by the Company and CAP America Trust. Interest on the loan is fixed at 6%,
payable monthly, with CAP America Trust having the right to reset the interest
rate to 200 basis points over 1-year LIBOR upon 30 days notice to the Company. A
variable fee payment based on the number of teeth whitening procedures performed
at Company-run teeth whitening Centers will commence on May 11, 2006 and
continue until May 10, 2011. Variable fees will be due within 40 days after the
end of the month in which the procedures are performed, except for fees due for
April/May 2011, which will be due on the maturity date. As of December 25, 2004,
$1.6 million has been drawn on the loan. CAP is a co-trustee of CAP America
Trust. CAP is also a co-trustee of the ERSE Trust. ERSE owns LCO, a principal
shareholder of the Company. Mr. Pilaro, a director and Chairman of the Board of
the Company, is also Chairman of CAP.
15
McKinsey & Company Study
During the quarter ended September 25, 2004, CAP paid McKinsey & Co., a
management consulting firm, approximately $746,000 to evaluate the Company's
marketing strategies and to make recommendations to improve the effectiveness of
its advertising. McKinsey & Co. has no relationship to the Company or to CAP.
The cost was recorded as a non-cash expense to BriteSmile with a corresponding
increase to Additional Paid In Capital. CAP is a co-trustee of the ERSE Trust.
Mr. Pilaro, a director and Chairman of the Board of the Company, is Chairman of
CAP, and ERSE owns LCO, a principal shareholder of the Company.
December 2004 Convertible Notes, Warrants and Additional Investment Rights
In December 2004, the Company issued $12 million in Notes, and related
Warrants and Rights to six investors. Among the investors, LCO purchased $1.0
million of the Notes, Warrants and Rights. The Notes are repayable in 36 equal
monthly installments commencing in June 2006, and bear interest at an annual
rate equal to the greater of 5% or six-month LIBOR as of 2 business days prior
to the start of each quarterly interest period plus 3% with a maximum interest
rate of 8% per annum. Principal and interest on the Notes is payable, at the
option of the Company, in cash or shares of the Company's common stock, subject
to certain limitations. The Notes are convertible into shares of the Company's
common stock at a per share conversion price of $7.61, subject to adjustment
from time to time upon the occurrence of certain other events described in the
Notes, including future issuances of common stock for consideration less than
the conversion price then in effect, stock splits or reverse stock splits, and
the occurrence of certain major corporate events such as mergers, sale of
assets, tender offers or exchange offers. The Warrants have a term of five years
and an exercise price of $7.61 per share, subject to adjustment upon certain
events specified in the Warrant, including the subsequent issuance by the
Company of shares of its common stock at prices lower than the original Warrant
exercise price. The Rights provide to the Investors the right to purchase
additional Notes and additional Warrants. The Rights are exercisable at any time
prior to the 180th trading day following the closing date of the transaction.
(See Proposal 4 - Ratification and Approval of Note, Warrant and Additional
Investment Rights Issuance.)
Housing Allowance for Dr. Feneley
Since May 2004, CAP provided a housing allowance to Dr. Feneley. The sum
of the payments, $67,000, was recorded by the Company as an expense and an
increase to Additional Paid-in Capital.
PART IV.
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(c) Exhibits
Exhibit Number
Per Item 601 of
Regulation S-K Title of Document
2 Asset Purchase Agreement and Plan of Reorganization by and
among BriteSmile, Inc., an Alabama corporation, BriteSmile,
Inc., a Utah corporation, and David K. Yarborough, together
with the exhibits and schedules forming part of the Asset
Purchase Agreement (incorporated by reference to the Company's
Annual Report on Form 10-K for the fiscal year ended December
27, 2003).
3.01 Articles of Restatement of the Articles of Incorporation of
the Company as filed with the Utah Division of Corporations
and Commercial Code on January 17, 2003 (incorporated by
reference to the Company's Annual Report on Form 10-K for the
fiscal year ended December 28, 2002).
3.02 Articles of Amendment to the Articles of Incorporation of the
Company as filed with the Utah Division of Corporations and
Commercial Code effective January 30, 2004 (incorporated by
reference to the Company's Annual Report on Form 10-K for the
fiscal year ended December 27, 2003).
3.03 Bylaws adopted May 2, 1996, (incorporated by reference to the
Company's Annual Report on Form 10-K for the fiscal year ended
March 31, 1996).
3.04 Amendment to Bylaws adopted July 23, 1999 (incorporated by
reference to the Company's Quarterly Report on Form 10-QSB for
the quarter ended June 30, 1999).
16
10.01 1990 Stock Option Plan for Employees of the Company
(incorporated by reference to the Company's Annual Report on
Form 10-KSB for the fiscal year ended March 31, 1996).
10.02 Securities Purchase Agreement dated April 1, 1996 for 300,000
shares of common stock and Options to Purchase 1,000,000
shares of common stock at $20 per share, between the Company,
LCO Investments Limited, Pinnacle Fund L.P., and Richard S.
Braddock (incorporated by reference to the Current Report on
Form 8-K of the Company dated April 1, 1996).
10.03 Registration Rights Agreement dated April 1, 1996 between the
Company, LCO Investments Limited, Richard S. Braddock, and
Pinnacle Fund, L.P. (incorporated by reference to the Current
Report on Form 8-K of the Company dated April 1, 1996).
10.04 Securities Purchase Agreement dated May 8, 1997 for 428,572
shares of common stock and Options to Purchase 500,000 shares
of common stock at $9.00 per share, among the Company, LCO
Investments Limited, and Richard S. Braddock (incorporated by
reference to the Company's Annual Report on Form 10-KSB for
the fiscal year ended March 31, 1997).
10.05 Registration Rights Agreement dated May 8, 1997 among the
Company, LCO Investments Limited, and Richard S. Braddock
(incorporated by reference to the Company's Annual Report on
Form 10-KSB for the fiscal year ended March 31, 1997).
10.06 Stock Purchase Agreement dated as of May 4, 1998 for 1,860,465
shares of common stock, between the Company and LCO
Investments Limited (incorporated by reference to the
Company's Annual Report on Form 10-KSB for the fiscal year
ended March 31, 1998).
10.07 Registration Rights Agreement dated as of May 4, 1998 between
the Company and LCO Investments Limited (incorporated by
reference to the Company's Annual Report on Form 10-KSB for
the fiscal year ended March 31, 1998).
10.08 Employment Letter dated January 20, 1999 between the Company
and John L. Reed (incorporated by reference to the Company's
Annual Report on Form 10-KSB for the year ended March 31,
1999).
10.09 Employment Letter dated April 19, 1999 between the Company's
subsidiary, BriteSmile International, Limited, and Paul Dawson
(incorporated by reference to the Company's Annual Report on
Form 10-KSB for the year ended March 31, 1999).
10.10 Revised 1997 Stock Option and Incentive Plan of the Company,
as amended through June 20, 2001 (incorporated by reference to
the Company's Annual Report on Form 10-K for the 52 weeks
ended December 29, 2001).
10.11 Form of Option Agreement between the Company and certain
directors of the Company (incorporated by reference to the
Company's Annual Report on Form 10-K for the 52 weeks ended
December 29, 2001).
10.12 Form of Option Agreement between the Company and certain
employees of the Company (incorporated by reference to the
Company's Annual Report on Form 10-K for the 52 weeks ended
December 29, 2001).
10.13 Form of Stock Purchase Agreement dated as of June 3, 1999,
between the Company and purchasers who acquired shares at a 5%
discount to the 10-day average market price preceding closing
(incorporated by reference to the Company's Current Report on
Form 8-K as filed June 21, 1999).
10.14 Registration Rights Agreement dated as of June 3, 1999 between
the Company and the non-management purchasers (incorporated by
reference to the Company's Current Report on Form 8-K as filed
June 21, 1999).
10.15 Amended and Restated Registration Rights Agreement dated as of
June 3, 1999 between the Company and the management purchasers
(incorporated by reference to the Company's Current Report on
Form 8-K as filed June 21, 1999).
10.16 Form of Stock Purchase Agreement dated as of June 3, 1999
between the Company and purchasers who acquired shares of
common stock of the Company at a 5% discount to the 10-day
average market price preceding closing (incorporated by
reference to the Company's Current Report on Form 8-K dated
June 4, 1999).
10.17 Registration Rights Agreement dated as of June 3, 1999 between
the Company and certain non-management purchasers in the June
1999 Private Placement (incorporated by reference to the
Company's Current Report on Form 8-K dated June 4, 1999).
10.18 Amended and Restated Registration Rights Agreement dated as of
June 3, 1999 between the Company and certain management
purchasers (incorporated by reference to the Company's Current
Report on Form 8-K as filed June 4, 1999).
17
10.19 Stock Purchase Agreement dated as of January 12, 1999 between
the Company and the Pequot investment funds ("Pequot Funds")
(incorporated by reference to the Company's Current Report on
Form 8-K dated January 18, 2000).
10.20 Registration Rights Agreement dated as of January 18, 2000
between the Company and the Pequot Funds (incorporated by
reference to the Company's Current Report on Form 8-K dated
January 18, 2000).
10.21 Voting and Co-sale Agreement dated as of January 18, 2000
between the Company, the Pequot Funds and LCO Investments Ltd.
(incorporated by reference to the Company's Current Report on
Form 8-K dated January 18, 2000).
10.22 Agreement of Sublease dated December 1999 between the Company
and LCO Properties, Inc. (incorporated by reference to the
Company's Annual Report on Form 10-KSB for the fiscal year
ended April 1, 2000).
10.23 Securities Purchase Agreement dated as of June 27, 2000
between the Company and certain purchasers of 5% Convertible
Subordinated Notes (incorporated by reference to the Company's
Transition Report on Form 10-K for the Nine-month Transition
Period ended December 30, 2000).
10.24 Form of Convertible Notes issued pursuant to the Securities
Purchase Agreement dated as of June 27, 2000 (incorporated by
reference to the Company's Transition Report on Form 10-K for
the Nine-month Transition Period ended December 30, 2000).
10.25 Form of Warrants granted to note purchasers pursuant to the
Securities Purchase Agreement dated as of June 27, 2000
(incorporated by reference to the Company's Transition Report
on Form 10-K for the Nine-month Transition Period ended
December 30. 2000).
10.26 Form of Registration Rights Agreement between the Company of
the purchasers of Notes pursuant to the Securities Purchase
Agreement dated as of June 27, 2000 (incorporated by reference
to the Company's Transition Report on Form 10-K for the
Nine-month Transition Period ended December 30, 2000).
10.27 Amendment Agreement dated as of August 3, 2000 between the
Company and the purchasers of notes identified therein
(incorporated by reference to the Company's Transition Report
on Form 10-K for the Nine-month Transition Period ended
December 30, 2000).
10.28 Note Purchase Agreement dated December 5, 2000 between the
Company and LCO Investments Limited (incorporated by reference
to the Company's Current Report on Form 8-K dated December 5,
2000).
10.29 Convertible Promissory Note dated December 5, 2000 in the
principal amount of $5,000,000 (incorporated by reference to
the Company's Current Report on Form 8-K dated December 5,
2000).
10.30 Warrant to Purchase 250,000 Shares of common stock of the
Company dated December 5, 2000 (incorporated by reference to
the Company's Current Report on Form 8-K dated December 5,
2000).
10.31 Amended and Restated Agreement between Excimer Vision Leasing
L.P. and the Company dated February 2001 (incorporated by
reference to the Company's Transition Report on Form 10-K for
the Nine-month Transition Period ended December 30, 2000).
10.32 Amendment dated September 18, 2002 to Amended and Restated
Agreement between Excimer Vision Leasing L.P. and the Company
dated February 2001 (incorporated by reference to the
Company's Annual Report on Form 10-K for the 52 weeks ended
December 28, 2002).
10.33 Amendment dated January 1, 2003 to Amended and Restated
Agreement between Excimer Vision Leasing L.P. and the Company
dated February 2001 (incorporated by reference to the
Company's Annual Report on Form 10-K for the 52 weeks ended
December 28, 2002).
10.34 Loan Agreement between Excimer Vision Leasing L.P. and the
Company dated as of March 1, 2001 (incorporated by reference
to the Company's Transition Report on Form 10-K for the
Nine-month Transition Period ended December 30, 2000).
10.35 Unsecured Credit Agreement between BriteSmile International
and CAP Advisers Limited dated March 2002 (incorporated by
reference to the Company's Annual Report on Form 10-K for the
52 weeks ended December 29, 2001).
10.36 Credit and Security Agreement dated December 13, 2001 between
BriteSmile International and CAP Advisers Limited
(incorporated by reference to the Company's Annual Report on
Form 10-K for the 52 weeks ended December 29, 2001).
18
10.37 Supplemental Agreement dated March 2002 to Credit and Security
Agreement dated December 13, 2001 between BriteSmile
International and CAP Advisers Limited (incorporated by
reference to the Company's Annual Report on Form 10-K for the
52 weeks ended December 29, 2001).
10.38 Supplemental Agreement dated July 19, 2002 to Credit and
Security Agreement dated December 13, 2001, as amended, and to
Unsecured Credit Agreement dated March 8, 2002 (incorporated
by reference to the Quarterly Report on Form 10-Q of the
Company for the 13 weeks ended June 29, 2002).
10.39 Supplemental Agreement dated January 9, 2003 to Credit and
Security Agreement dated March 2002 (incorporated by reference
to the Company's Annual Report on Form 10-K for the 52 weeks
ended December 28, 2002).
10.40 Amendment to Lease Agreement between Excimer Vision Leasing
L.P. and the Company dated March 8, 2002 (incorporated by
reference to the Company's Annual Report on Form 10-K for the
52 weeks ended December 29, 2001).
10.41 Form of Guaranty of Fiscal 2002 Shortfall Summary of Terms
dated March 2002 in connection with commitments from certain
shareholders and/or directors of the Company to secure up to
$4 million of additional working capital (incorporated by
reference to the Company's Annual Report on Form 10-K for the
52 weeks ended December 29, 2001).
10.42 Form of Convertible Note Purchase Agreement used in connection
with November 20, 2002 convertible note offering (incorporated
by reference to the Current Report on Form 8-K of the Company
filed on November 25, 2002).
10.43 Form of Convertible Promissory Note issued in connection with
November 20, 2002 convertible note offering (incorporated by
reference to the Current Report on Form 8-K of the Company
filed on November 25, 2002).
10.44 CAP Line Conversion Agreement dated as of November 20, 2003
between the Company and LCO Investments Limited (incorporated
by reference to the Current Report on Form 8-K of the Company
filed on November 28, 2003).
10.45 Demand Promissory Note dated November 20, 2003 payable by the
Company to LCO Investments Limited in the principal amount of
$2,000,000 (incorporated by reference to the Current Report on
Form 8-K of the Company filed on November 28, 2003).
10.46 Amendment to Lease Agreement between Excimer Vision Leasing
L.P. and the Company dated December 12, 2003 (incorporated by
reference to the Company's Annual Report on Form 10-K for the
fiscal year ended December 27, 2003).
10.47 Receivable Conversion Agreement dated November 20, 2003
between the Company and Excimer Vision Leasing L.P.
(incorporated by reference to the Company's Annual Report on
Form 10-K for the fiscal year ended December 27, 2003).
10.48 Amended and Restated Consulting Agreement dated December 27,
2003 between the company and John Warner (incorporated by
reference to the Company's Annual Report on Form 10-K for the
fiscal year ended December 27, 2003).
10.49 Employment Agreement, Confidentiality and Rights Ownership
Agreement, Common Stock Purchase Option and Restricted Stock
Grant Agreement each dated January 9, 2005 between the Company
and Gregg A. Coccari (incorporated by reference to the
Company's Annual Report on Form 10-K for the fiscal year ended
December 25, 2004).
10.50 Form of Securities Purchase Agreement dated as of December 16,
2004, between the Company and the Investors, together with
exhibits including form of Senior Convertible Note dated
December 16, 2004, due December 16, 2009; form of Warrant to
Purchase Common Stock of the Company dated December 16, 2004;
and form of Additional Investment Right between the Company
and the Investors (incorporated by reference to the Current
Report on Form 8-K of the Company filed on December 21, 2004).
10.51 July 2003 Assert Purchase Agreement between BDI and R. Eric
Montgomery (incorporated by reference to the Quarterly Report
on Form 10-Q of the Company filed on August 12, 2003).
10.52 Consulting Agreement between BDI and Oraceutical Innovative
Properties (incorporated by reference to the Quarterly Report
on Form 10-Q of the Company filed on August 12, 2003).
19
10.53 $2 million promissory note issued by BDI to LCO Investments
Limited (incorporated by reference to the Quarterly Report on
Form 10-Q of the Company filed on August 12, 2003).
10.54 Supply Agreement dated December 21, 2004 between the Company
and Oraceutical, LLC (filed herewith).
10.55 $2.5 million loan agreement between BriteSmile and CAP America
Trust: See Agreement dated May 7, 2003 between the Company and
CAP America Trust (filed herewith).
14 Code of Ethics (incorporated by reference to the Company's
Annual Report on Form 10-K for the fiscal year ended December
27, 2003).
21 Subsidiaries of the Company (incorporated by reference to the
Company's Annual Report on Form 10-K for the fiscal year ended
December 25, 2004).
23.1 Consent of Independent Registered Public Accounting Firm
(incorporated by reference to the Company's Annual Report on
Form 10-K for the fiscal year ended December 25, 2004).
31.1 Certification of Principal Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
31.2 Certification of Chief Financial Officer pursuant to Section
302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
32.1 Certification of Chief Executive Officer pursuant to Section
906 of the Sarbanes-Oxley Act of 2002 (incorporated by
reference to the Company's Annual Report on Form 10-K for the
fiscal year ended December 25, 2004).
32.2 Certification of Chief Financial Officer pursuant to Section
906 of the Sarbanes-Oxley Act of 2002 (incorporated by
reference to the Company's Annual Report on Form 10-K for the
fiscal year ended December 25, 2004).
--------------------
* Denotes management contract or compensatory plan or arrangement.
20
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized.
BriteSmile, Inc.
By: /s/ Julian Feneley
------------------------------------------------
Julian Feneley
President
(Principal Executive Officer)
Date: August 25, 2005
By: /s/ Ken Czaja
------------------------------------------------
Ken Czaja
EVP, Chief Financial Officer
(Principal Financial and Accounting Officer)
Date: August 25, 2005